CSL Behring Gets Indication For Acquired Factor XIII Deficiency For Fibrogammin P In Japan
This article was originally published in PharmAsia News
Executive Summary
CSL Behring on Sept. 13 obtained approval in Japan for the use of plasma derivative Fibrogammin P, the purified concentrate of blood coagulation factor XIII, for the treatment of bleeding caused by acquired factor XIII deficiency.
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 9 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.